$MNKD

Thomson David sold $98K of MNKD

Thomson David (EVP Genl Counsel & Secretary) sold 24,109 shares of MANNKIND CORP (MNKD) at $4.05 on 2026-07-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Thomson David
Published Jul 17, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 5:50 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MNKD
Neutral
medium confidence
Mentioned
$MNKD
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MNKDNeutralLow
01

Why it matters

The newest disclosed fact is the specific open-market sale details (shares, price, total value) by an executive under a pre-arranged 10b5-1 plan.

02

Market read

This is a routine insider sale disclosure with limited incremental information beyond confirming the transaction occurred.

03

What to watch

Traders may over-weight insider selling; without accompanying buy/sell patterns, guidance, or operational updates, the signal is weak.

Relevance 2/10Novelty 3/10Timing: filed 2026-07-17 (same day as transaction)

Background

The article is a primary-source SEC Form 4 insider transaction for MannKind Corp (MNKD).

Company-level read

Ticker impact

$MNKDNeutralMedium confidence
Context

MannKind disclosed an EVP general counsel and secretary open-market sale of 24,109 shares at $4.05 on 2026-07-17 under a 10b5-1 plan.

Expected impact

Likely minimal, though it can add short-term overhang if traders interpret it as bearish.

Evidence & confidence

Form 4 insider sales are common and the article specifies a pre-arranged 10b5-1 plan, which reduces the likelihood of information asymmetry. The disclosed size is moderate relative to typical large-cap flows, and no other MNKD-specific catalyst is provided.

Market effects

No sector-level implications; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than a view on MNKD prospects.

Key entities

  • MANNKIND CORP

    US-listed company whose Form 4 insider sale was disclosed.

  • Thomson David

    EVP, General Counsel and Secretary who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MNKDMedAI 8/10

MannKind Advances Inhaled IPF Drug to Global Phase 2, Eyes FUROSCIX Growth

MannKind (MNKD) advances inhaled IPF drug to global Phase 2, with potential human testing by year-end. CEO Castagna highlights FUROSCIX's strong adoption, shifting sales focus to nephrology. Company reports sufficient cash for growth, aiming for profitability next year. Vicore Pharma's Phase 2b study for IPF treatment expected to report results in summer 2025.

$MNKDMedAI 8/10

A heart-failure injector delivers a full dose in under 10 seconds. Urine output was similar to treatment into a vein.

MannKind (MNKD) presented clinical data at HFSA 2026 showing Furoscix ReadyFlow's comparable urine output to IV furosemide. The autoinjector delivers an 80 mg/mL dose in under 10 seconds, with 91.3% and 92.7% bioavailability in thigh and upper-arm injections, respectively. ReadyFlow received FDA approval in July 2026 for fluid overload treatment in heart failure or CKD patients.